[Ca2+]i-reducing action of cAMP in rat pancreatic beta-cells: involvement of thapsigargin-sensitive stores.
In the present study, we examined the ability of adenosine 3',5'-cyclic monophosphate (cAMP) to reduce elevated levels of cytosolic Ca2+ concentration ([Ca2+]i) in pancreatic beta-cells. [Ca2+]i and reduced pyridine nucleotide, NAD(P)H, were measured in rat single beta-cells by fura 2 and autofluorescence microfluorometry. Sustained [Ca2+]i elevation, induced by high KCl (25 mM) at a basal glucose concentration (2.8 mM), was substantially reduced by cAMP-increasing agents, dibutyryl cAMP (DBcAMP, 5 mM), an adenylyl cyclase activator forskolin (10 microM), and an incretin glucagon-like peptide-1-(7-36) amide (10(-9) M), as well as by glucose (16.7 mM). The [Ca2+]i-reducing effects of cAMP were greater at elevated glucose (8.3-16.7 mM) than a basal glucose (2.8 mM). An inhibitor of protein kinase A (PKA), H-89, counteracted [Ca2+]i-reducing effects of cAMP but not those of glucose. Okadaic acid, a phosphatase inhibitor, at 10-100 nM also reduced sustained [Ca2+]i elevation in a concentration-dependent manner. Glucose, but not DBcAMP, increased NAD(P)H in beta-cells. [Ca2+]i-reducing effects of cAMP were inhibited by 0.3 microM thapsigargin, an inhibitor of the endoplasmic reticulum (ER) Ca2+ pump. In contrast, [Ca2+]i-reducing effects of cAMP were not altered by ryanodine, an ER Ca(2+)-release inhibitor, Na(+)-free conditions, or diazoxide, an ATP-sensitive K+ channel opener. In conclusion, the cAMP-PKA pathway reduces [Ca2+]i elevation by sequestering Ca2+ in thapsigargin-sensitive stores. This process does not involve, but is potentiated by, activation of beta-cell metabolism. Together with the known [Ca2+]i-increasing action of cAMP, our results reveal dual regulation of beta-cell [Ca2+]i by the cAMP-signaling pathway and by a physiological incretin.
Yaekura
K
K
Department of Physiology, Kagoshima University School of Medicine, Japan.
Yada
T
T
D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D000242:Cyclic AMP / Q000494:pharmacology*; D003600:Cytosol / Q000187:drug effects / Q000378:metabolism; D004721:Endoplasmic Reticulum / Q000378:metabolism; D004734:Energy Metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005934:Glucagon / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000494:pharmacology; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011498:Protein Precursors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D019831:Sodium-Calcium Exchanger / Q000378:metabolism; D019284:Thapsigargin / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D011498:Protein Precursors; D019831:Sodium-Calcium Exchanger; D009249:NADP; D003994:Bucladesine; D011189:Potassium Chloride; D019284:Thapsigargin; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000242:Cyclic AMP; D005947:Glucose; D002118:Calcium